PFSA▲
Profusa Regains Compliance with Nasdaq Publicly Held Shares Rule
Profusa, Inc. announced that it has received a notice from Nasdaq stating that after its 1-for-4 reverse stock split on August 14, 2026, it fell below the required 500,000 publicly held shares, but following correspondence on August 21, 2026, Nasdaq determined the company complies with the rule and has closed its review. The notice does not affect the listing or trading of Profusa's securities, which continue on the Nasdaq Capital Market under the symbol PFSA. The company made the announcement in accordance with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications. Profusa, based in Berkeley, California, develops tissue-integrated biosensors for medical and personal use.
PFSA
Profusa Announces 1-for-4 Reverse Stock Split
Profusa, Inc. announced it has filed an amendment to its certificate of incorporation to effect a one-for-four reverse stock split of its common stock. The reverse split will take effect at 12:01 am Eastern Time on August 17, 2026, and the stock will begin trading on a post-split basis on The Nasdaq Capital Market that day under the existing ticker symbol PFSA with a new CUSIP number. As a result, every four shares outstanding will be consolidated into one share, reducing the number of outstanding shares from 2,422,906 to approximately 605,726, while authorized shares remain at 601 million. No fractional shares will be issued; stockholders entitled to fractional shares will receive cash payments instead.
Profusa signs option agreement to acquire G3 Vision Labs
Profusa has signed an option agreement giving it the right to acquire commercial-stage diagnostics company G3 Vision Labs and its subsidiaries, which together generated estimated unaudited net revenues of approximately $111 million in 2025. The option is exercisable until 90 days after G3 delivers specified financial information, subject to conditions including Profusa raising at least $30 million in financing, refinancing or satisfying certain G3 indebtedness, and obtaining Nasdaq and stockholder approvals. As consideration for the option, Profusa issued 201,120 shares of common stock and 52,903.566 shares of a newly designated non-voting convertible preferred stock, with each preferred share convertible into 1,000 common shares upon stockholder approval. If the option is exercised, the combined company would operate as a public diagnostics company with national CLIA-certified laboratories serving addiction treatment, pain management, and behavioral health providers. The agreement does not constitute a change of control, and G3 stockholders retain the consideration if the option remains unexercised.
PFSA▼
Profusa Stock Falls 19% After Announcing Diagnostics Acquisition
Profusa shares dropped 19% in pre-market trading after the digital health company announced a non-binding term sheet to acquire a privately held commercial-stage diagnostics and toxicology testing company. The target company reported estimated 2025 net revenues of approximately $111 million based on unaudited management information. Under the contemplated transaction, Profusa will issue common shares equal to 19.99% of its outstanding shares to the target's stockholders, with the remainder in non-voting convertible preferred stock, subject to shareholder approval. Profusa also expects to close on approximately $7 million in financing through a convertible note with a 12-month term, a 9% original issue discount, and a 7% interest rate that rises to 18% upon default. The company implemented a 1-for-25 reverse stock split on July 7, 2026, and announced management changes including the appointment of Jack Stover as Executive Chairman and CEO.
Profusa Plunges Following 1-for-25 Reverse Stock Split Announcement
Profusa announced a 1-for-25 reverse stock split, sending shares down 28.08% to $0.09 on Thursday and a further 3.85% to $0.08 in overnight trading. The split takes effect at 12:01 am Eastern Time on July 7, 2026, with shares trading on a post-split basis on Nasdaq under the existing ticker PFSA but a new CUSIP number. Every 25 shares will be consolidated into one, reducing outstanding shares from approximately 13.2 million to about 0.53 million, while authorized shares remain at 601 million and the par value stays at $0.0001 per share. The stock has traded between $0.08 and $412.50 over the past year.
USA